Brian Posner Buys 2,000 Shares of Dyne Therapeutics (NASDAQ:DYN) Stock

Dyne Therapeutics, Inc. (NASDAQ:DYN) Director Brian Posner bought 2,000 shares of the company’s stock in a transaction dated Tuesday, May 26th. The stock was purchased at an average cost of $18.21 per share, for a total transaction of $36,420.00. Following the completion of the acquisition, the director owned 20,000 shares in the company, valued at $364,200. This trade represents a 11.11% increase in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link.

Dyne Therapeutics Stock Up 4.1%

Dyne Therapeutics stock opened at $19.33 on Friday. The stock has a market cap of $3.20 billion, a P/E ratio of -6.00 and a beta of 1.08. The company has a quick ratio of 19.92, a current ratio of 19.92 and a debt-to-equity ratio of 0.17. Dyne Therapeutics, Inc. has a twelve month low of $8.06 and a twelve month high of $25.00. The company’s 50-day moving average price is $18.29 and its two-hundred day moving average price is $18.31.

Dyne Therapeutics (NASDAQ:DYN) last released its quarterly earnings results on Monday, May 11th. The company reported ($0.73) earnings per share for the quarter, beating the consensus estimate of ($0.77) by $0.04. During the same quarter in the prior year, the firm earned ($1.05) earnings per share. As a group, analysts expect that Dyne Therapeutics, Inc. will post -3 EPS for the current year.

Wall Street Analyst Weigh In

Several research analysts have weighed in on DYN shares. Sanford C. Bernstein increased their price target on shares of Dyne Therapeutics from $23.00 to $24.00 and gave the company a “market perform” rating in a report on Wednesday, May 13th. HC Wainwright lowered their price target on shares of Dyne Therapeutics from $60.00 to $50.00 and set a “buy” rating on the stock in a report on Tuesday, March 3rd. Chardan Capital reissued a “buy” rating and issued a $38.00 price target on shares of Dyne Therapeutics in a report on Monday, March 9th. Evercore set a $33.00 price target on shares of Dyne Therapeutics in a report on Friday, May 15th. Finally, Weiss Ratings reissued a “sell (d-)” rating on shares of Dyne Therapeutics in a report on Monday, April 20th. Three investment analysts have rated the stock with a Strong Buy rating, eleven have assigned a Buy rating, two have issued a Hold rating and one has assigned a Sell rating to the stock. According to data from MarketBeat.com, the company currently has an average rating of “Moderate Buy” and a consensus target price of $35.00.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently made changes to their positions in the business. Creative Planning boosted its position in Dyne Therapeutics by 6.8% in the third quarter. Creative Planning now owns 15,527 shares of the company’s stock valued at $196,000 after buying an additional 986 shares in the last quarter. Mirae Asset Global Investments Co. Ltd. raised its stake in shares of Dyne Therapeutics by 25.3% during the third quarter. Mirae Asset Global Investments Co. Ltd. now owns 5,500 shares of the company’s stock valued at $70,000 after acquiring an additional 1,109 shares during the last quarter. Hilton Head Capital Partners LLC bought a new position in shares of Dyne Therapeutics during the first quarter valued at $26,000. Caxton Associates LLP raised its stake in shares of Dyne Therapeutics by 10.9% during the second quarter. Caxton Associates LLP now owns 16,599 shares of the company’s stock valued at $158,000 after acquiring an additional 1,627 shares during the last quarter. Finally, China Universal Asset Management Co. Ltd. raised its stake in shares of Dyne Therapeutics by 9.2% during the third quarter. China Universal Asset Management Co. Ltd. now owns 24,937 shares of the company’s stock valued at $315,000 after acquiring an additional 2,108 shares during the last quarter. Institutional investors and hedge funds own 96.68% of the company’s stock.

About Dyne Therapeutics

Dyne Therapeutics is a clinical-stage biotechnology company specializing in the development of localized gene regulation therapies for serious rare diseases. The company’s proprietary FORCE (Facilitated Orthogonal Receptor‐mediated Cargo Evaluation) platform is designed to enable targeted delivery of oligonucleotide and gene therapy modalities to skeletal and respiratory muscles. Dyne’s lead programs focus on Duchenne muscular dystrophy (DMD), myotonic dystrophy type 1 (DM1) and facioscapulohumeral muscular dystrophy (FSHD), with preclinical and early clinical studies evaluating safety, tolerability and tissue specificity.

Since its founding in 2019 by Flagship Pioneering, Dyne has advanced multiple product candidates using its modular delivery approach, which couples engineered ligands with therapeutic payloads to improve uptake into muscle cells.